HEALTH TECHNOLOGY

Sameday Health Launches Strep and Flu Testing in Nationwide Clinics

Sameday Health | August 16, 2022 | Read time : 02:00 min

Sameday Health

Sameday Health, a world-class testing and wellness provider, announced the rollout of strep and flu testing across participating Sameday Health clinics nationwide, including in California, New York, and Washington D.C. The new tests are offered individually and in bundles, giving clients the opportunity to receive strep, flu and COVID-19 tests together for a discounted price.

Each year, strep throat and the flu affect millions of Americans. According to the CDC, up to 25,000 cases of invasive "group A" strep disease occur annually in the United States. The CDC also estimates that last year's flu season caused up to 13 million related illnesses and 6.1 million medical visits.

Particularly with back-to-school season on the horizon, strep and flu testing services will become more critical to keep communities healthy.

"At Sameday Health, we've intentionally spent the past year bolstering our infrastructure to enable the expansion of our diagnostic testing services and further safeguard the health of our communities. We're proud to facilitate better health outcomes for our clients by offering services, now including strep and flu testing, that deliver peace of mind and the information they need to lead healthier, fuller lives."

Felix Huettenbach, Sameday Health CEO and Founder

"As common viruses and infections reemerge during the fall months – on top of new COVID-19 variants – it's important to quickly receive clarity on whether a condition is strep, flu, COVID-19, or another illness," Patrick Emad, Sameday Health's Executive Vice President of Clinics. "Our comprehensive testing helps to minimize the spread of illnesses, boost proper diagnoses, and expedite symptom relief."

Sameday Health's strep and flu testing joins their other reliable and convenient same-day medical services, including COVID-19 testing, panel testing, IV drip therapy, wellness injections, and urgent care.

About Sameday Health
Sameday Health is dedicated to healthcare as a complete experience, not simply a service. Our purpose is to create healthcare that centers around the client, combining a human approach with intuitive technology. We offer quality, personalized care wherever you are including in our clinics or at your door.

Inspired by the lotus flower's ability to grow in even the toughest terrains, Sameday Health is determined to create a sense of hope and help with our clients. Since opening our first clinic in Venice, CA at the height of the COVID 19-pandemic, the Sameday team has been focused on closing gaps in the healthcare system from testing to wellness to care. Devoted to responding immediately to our client's needs, we are providing expanded same day healthcare in our locations including Los Angeles, San Francisco, New York, Miami, DC, Boston, and more.

 

Spotlight

Why do medical device companies choose Microsoft Dynamics GP? It’s simple. Dynamics GP offers an agile, long-term solution that supports and scales with life science companies, from emerging start-up to pre-IPO.

Spotlight

Why do medical device companies choose Microsoft Dynamics GP? It’s simple. Dynamics GP offers an agile, long-term solution that supports and scales with life science companies, from emerging start-up to pre-IPO.

Related News

HEALTH TECHNOLOGY

Pure Health UAE Largest Healthcare Platform Signs a Deal With Equity Group Investments to Invest Half a Billion Dollars in a U.S. Healthcare Company

Pure Health | September 05, 2022

Alpha Dhabi Holding subsidiary, Pure Health, the largest integrated healthcare platform of the United Arab Emirates announced that it has entered into a definitive purchase agreement to acquire a minority equity investment in Ardent Health Services a leading U.S. healthcare provider based in Nashville, Tennessee, for a total investment of $500 million. The investment is subject to customary closing conditions and will be finalized after receipt of all necessary U.S. regulatory approvals. Ardent is the fourth largest privately held acute care hospital operator in the U.S., with 30 hospitals and more than 200 sites of care across six states, and approximately 26,000 employees. Pure Health would achieve a minority equity investment by purchasing an interest in Ardent from Equity Group Investments a Chicago-based private investment firm and majority owner of Ardent. As part of its investment, Pure Health would receive board observer rights but would not have a seat on Ardent’s board of directors. The investment does not include plans for either the expansion of Ardent’s physical footprint or collaboration between Ardent and Pure Health in the delivery of care. Equity Group Investments hosted a signing ceremony, which included Farhan Malik, CEO of Pure Health, Sam Zell, founder and chairman of EGI, and Marty Bonick, president and chief executive officer of Ardent. “One of EGI’s strengths is partnering with like-minded individuals with the experience and passion for how we approach investment opportunities. We look forward to developing a productive relationship with Pure Health as they continue to explore the various dynamics of the U.S. healthcare system,” Sam Zell Commenting on the major investment announcement, Farhan Malik said, “This landmark investment agreement marks a quantum leap for the UAE and the global healthcare industry.” “This is an exciting opportunity for Pure Health, as we continue to build relationships with leading U.S. healthcare providers to leverage the highest standards and best clinical practices to provide an unrivalled healthcare experience for patients in the UAE,” said Malik. “Ardent has a strong track record of delivering outstanding services across the United States, and we look forward to gaining additional knowledge to support our north star of advancing the science of longevity and unlocking time for humanity.” ABOUT PURE HEALTH Pure Health is an integrated healthcare solutions platform with a diversified portfolio of over 25 hospitals and more than 100 clinics offering 200+ specialties covering services from tertiary care to primary care; health insurance that covers over 2.5 million members; group procurement organization; over 150 laboratories; diagnostics services; rehab services; long term care; medical supplies; and health technology services. With more than 50 million annual clinical encounters and over 25,000 employee strength, the company provides healthcare services across the entire continuum of care. Pure Health is committed to enhancing longevity and helping people live longer, happier, and healthier lives. The company’s centers of excellence bring together clinical knowledge, process expertise, technology, and analytics to deliver outcome-focused, world-class quality across all channels of healthcare with a mandate to future-proof the healthcare system for a world of technological singularity. ABOUT EQUITY GROUP INVESTMENTS Equity Group Investments (EGI), founded by Sam Zell more than 50 years ago, has a long track record of building public and private businesses, including the origination and growth of multi-billion-dollar companies. EGI’s flexible capital and open investment mandate enable the firm to pursue opportunistic transactions across industries and geographies, throughout the capital structure, at any point in the economic cycle. EGI’s current portfolio includes investments in transportation and logistics, health care, manufacturing, agribusiness, energy, retail, waste and infrastructure, and real estate. ABOUT ARDENT HEALTH SERVICES Ardent Health Services invests in people, technology and communities. Through its subsidiaries, Ardent owns and operates 30 hospitals and more than 200 sites of care in six states with approximately 26,000 employees, including 1,200+ employed providers. With a focus on evidence-based practices to improve quality care and patient outcomes, four Ardent hospitals were named to Leapfrog’s Top Hospitals in 2021, and eight Ardent hospitals received a Leapfrog Hospital Safety Grade of A for Spring 2022. Based in Nashville, Tennessee, Ardent is owned by current and former members of Ardent’s management team; Equity Group Investments (EGI), a Chicago-based private investment firm; and Ventas, Inc.

Read More

HEALTH TECHNOLOGY

KORU Medical Systems Joins Subcutaneous Drug Development & Delivery Consortium

KORU Medical | October 05, 2022

KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, announced its membership in the Subcutaneous (SC) Drug Development & Delivery Consortium making it one of the first device companies to be added to the Consortium. “The Consortium creates an important forum to identify and address key challenges and opportunities across the SC field. Key industry experts can collaborate on issues at the clinical, regulatory, and commercial level and work towards advancing the SC market and creating the best outcomes for patients. I am excited for KORU Medical’s membership as one of the first device companies and look forward to advancing SC drug delivery.” Linda Tharby, KORU Medical’s President and CEO The Consortium was convened in 2018 as a community of well-recognized industry experts with decades of experience in the pharmaceutical drug delivery, device development, and commercialization space. The Consortium was built upon a strong desire for clear and transparent evidence-based communication of existing SC technologies and information. The Consortium’s mission is to identify current and future unmet medical needs within a dynamic SC drug delivery and development environment to transform patient care and improve patient outcomes. As a member, KORU Medical will contribute to advancing understanding of patient preference for SC therapy and the clinical trial strategy and technology for high-volume SC drugs. KORU Medical was one of the first companies to develop technology for SC biologics with volumes above 5mL, and its Freedom System is used by over 25,000 patients today to receive SC therapy. KORU Medical is established as the market leader in above 10mL and will bring this deep expertise in patient experience and subcutaneous injection technology to the Consortium. About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

Read More

HEALTH TECHNOLOGY

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

LifeTech Scientific Corporation | September 06, 2022

LifeTech Scientific Corporation is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States, meaning that all patient enrollment of the clinical trial will be fully covered by the USA medical insurance. This is expected to facilitate the marketing and registration process of the innovative device in the United States and provide strong clinical data to support the development of the device in the global market. The investigator-initiated pre-market clinical trial received FDA approval in March 2022. This prospective, randomized, controlled, multicenter clinical trial aims to evaluate the safety and efficacy of the implantation of LAmbre™ Plus LAA occluder in non-valvular atrial fibrillation patients with large and/or irregularly shaped appendages, as compared to oral anticoagulants. The trial is planning to enroll more than 3,000 subjects from up to 75 investigational sites in the United States and undertake more than 1,500 implantations of the LAmbre™ Plus LAA occluders at a fee. After reaching the established clinical objectives and conditions, the company will submit the marketing application of the device to the FDA. "This is a great milestone in LifeTech's international roadmap. Our LAA occluders had been successfully implanted in the United States on a basis of 'compassionate use', providing a new treatment for non-valvular atrial fibrillation patients with irregularly shaped appendages. Today, the approval for the first ever USA based investigator-initiated pre-market clinical trial and the medical insurance coverage gives us a greater confidence to further accelerate our process for providing this innovative, safe and effective stroke prevention solution to patients in the United States," Mr. Xie Yuehui, Chairman and CEO, LifeTech Scientific Corporation About the LAmbre™ Plus LAA Closure System LAmbre™ Plus LAA Closure System is independently developed by LifeTech Scientific Corporation. The device closes patient's left atrial appendage through percutaneous occlusion procedure to prevent stroke caused by detachment of thrombus from the left atrial appendage. LAmbre™ Plus LAA Closure System is a structural optimized version of the LAmbre™ LAA Closure System, which is an advanced medical device in the industry in terms of design and technology, and currently it has been widely used in over 40 countries with nearly 20,000 cases in clinical application around the world. About LifeTech Scientific Corporation Established in 1999, LifeTech Scientific Corporation (1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The company has a comprehensive product portfolio in the treatment of structural heart diseases, peripheral vascular diseases, bradycardia, neurological, neoplastic and respiratory diseases, alongside a unique iron-based bioresorbable technology. To date, 14 of the company's products have been approved as innovative medical devices by the National Medical Products Administration, and with a global reach of over 100 countries and regions, the company is currently one of the few domestic companies in China with a highly internationalized business structure.

Read More